New drug combo for advanced esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs (adebelimab, apatinib, and chemotherapy or chemoradiation) for people with esophageal cancer that has gotten worse after prior immunotherapy. It aims to see if this combination can help when standard first-line treatment stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell cancer that got worse or caused side effects after first treatment with chemotherapy and an immunotherapy drug.
- You are between 18 and 75 years old and in generally good health (able to take care of yourself).
- Depending on your symptoms, you may get either chemoradiation or chemotherapy along with the study drugs.
- You have at least one tumor that shows up on scans and can be measured.
- Your blood counts, kidney and liver function are within safe limits.
- You do not have active autoimmune disease or other serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
This study tests a combination of two drugs (a type of immunotherapy called adebrelimab and an immune-boosting drug called thymalfasin) given with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve the chances of a successful surgery.
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.